Taurine inhibits apolipoprotein E4 aggregation
| Autoři | |
|---|---|
| Rok publikování | 2026 |
| Druh | Recenzovaný odborný článek |
| Časopis / Zdroj | BIOMEDICINE & PHARMACOTHERAPY |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/pii/S0753332226004300?fr=RR-2&ref=pdf_download&rr=a221f1346d6eb190 |
| Doi | https://doi.org/10.1016/j.biopha.2026.119395 |
| Klíčová slova | aggregation; apolipoprotein E4; taurine; therapeutic potential |
| Přiložené soubory | |
| Popis | Apolipoprotein E4 (ApoE4) is a major genetic risk factor in many neurodegenerative diseases, yet effective therapeutic strategies targeting its associated pathologies remain unresolved. The aggregation of ApoE4, a key pathological feature, is modulated by tramiprosate and its metabolite 3-sulfopropanoic acid. In this study, we provide mechanistic insights into how taurine, a close chemical analogue of tramiprosate, interacts with ApoE4 and may similarly modulate its aggregation behavior. Using an integrated approach, which included molecular dynamics simulations, static light scattering, mass spectrometry, and cerebral organoid models, we investigated the effects of taurine on ApoE4 aggregation. Our results indicate that taurine effectively prevents ApoE4 ag gregation and exerts a partial disaggregating effect on pre-formed aggregates. Notably, taurine modulates mo lecular and cellular features associated with the ApoE4 isoform, shifting them toward patterns observed in the more benign ApoE3 isoform. These observations are consistent with effects similar to those reported for tra miprosate and 3-sulfopropanoic acid and suggest that taurine influences ApoE4-related molecular mechanisms, particularly in the context of the high-risk ApoE4/E4 genotype |
| Související projekty: |
|